Association between calprotectin and volatile fatty acids in patients with inflammatory bowel diseases

Authors

DOI:

https://doi.org/10.14739/2310-1210.2023.2.263222

Keywords:

fecal calprotectin, volatile fatty acids, butyric acid, propionic acid, ulcerative colitis, Crohn’s disease

Abstract

Aim. To evaluate the content of calprotectin and volatile fatty acids (VFAs) in feces of patients with inflammatory bowel disease (IBD).

Materials and methods. 61 patients (33 men and 28 women) with IBD aged 20 to 66 years (the mean indicator was 41.80 ± 1.14 years) were examined. The patients were treated in the Department of Intestinal Diseases of SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”. All the patients were divided into two groups: Group I – 46 patients with ulcerative colitis (UC) and Group II – 15 patients with Crohn’s disease (CD). The control group consisted of 10 practically healthy people (donors).

Calprotectin detection in fecal samples was carried out using a kit “Immundiagnostik”, Germany. Fecal VFAs were analyzed using a hardware-software complex for medical research with a gas chromatograph Chromatek-Crystal 5000.

Results. A significant increase in the content of fecal calprotectin was found. Its amount depended on the disease nosology and was more expressed in patients with UC (3.5 times higher (P < 0.05) than that in patients with CD). The observed changes were accompanied by an increase in the content of propionic (C3) acid and a decrease in acetic (C2), butyric (C4) acids in coprofiltrates of the examined patients. The detected imbalance in the fecal content of VFAs in patients led to an increase in the amount of fatty acids, which was more pronounced in patients with CD. An association between calprotectin levels and fecal VFA content was identified. Thus, correlation analysis allowed to establish a relationship between calprotectin levels and propionic acid content in patients with IBD (r = 0.370; P = 0.046).

Conclusions. In the case of active bowel inflammation, there is the increase in the fecal content of calprotectin and the decrease in VFAs (acetic and butyric acids) in accordance with the degree of disease activity, which allows the use of these indicators to assess the efficacy of therapies.

Author Biographies

Yu. M. Stepanov, SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro

MD, PhD, DSc, Professor, Corresponding Member of the National Academy of Medical Sciences of Ukraine, Director of the SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro

I. A. Klenina, SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro

PhD, Head of the Research Sector

O. M. Tatarchuk, SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro

PhD, Senior Researcher of the Research Sector

M. V. Stoikevych, SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro

MD, PhD, Head of the Department of Intestinal Diseases

Т. S. Tarasova, SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro

MD, Post-graduate Student, Department of Intestinal Diseases

N. S. Fedorova, SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro

MD, PhD, Senior Researcher of the Department of Intestinal Diseases

O. P. Petishko, SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro

Researcher of the Department of Scientific-Organizational, Methodical Work and Information Technologies

References

Ananthakrishnan, A. N., Kaplan, G. G., & Ng, S. C. (2020). Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century. Clinical Gastroenterology and Hepatology, 18(6), 1252-1260. https://doi.org/10.1016/j.cgh.2020.01.028

Flynn, S., & Eisenstein, S. (2019). Inflammatory Bowel Disease Presentation and Diagnosis. The Surgical Clinics of North America, 99(6), 1051-1062. https://doi.org/10.1016/j.suc.2019.08.001

Carstens, A., Dicksved, J., Nelson, R., Lindqvist, M., Andreasson, A., Bohr, J., Tysk, C., Talley, N. J., Agréus, L., Engstrand, L., & Halfvarson, J. (2019). The Gut Microbiota in Collagenous Colitis Shares Characteristics With Inflammatory Bowel Disease-Associated Dysbiosis. Clinical and Translational Gastroenterology, 10(7), e00065. https://doi.org/10.14309/ctg.0000000000000065

Yamamoto-Furusho, J. K., Bosques-Padilla, F., de-Paula, J., Galiano, M. T., Ibañez, P., Juliao, F., Kotze, P. G., Rocha, J. L., Steinwurz, F., Veitia, G., & Zaltman, C. (2017). Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México, 82(1), 46-84. https://doi.org/10.1016/j.rgmx.2016.07.003

Seyedian, S. S., Nokhostin, F., & Malamir, M. D. (2019). A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. Journal of Medicine and Life, 12(2), 113-122. https://doi.org/10.25122/jml-2018-0075

Annese, V. (2020). Genetics and epigenetics of IBD. Pharmacological Research, 159, 104892. https://doi.org/10.1016/j.phrs.2020.104892

Chang, J. T. (2020). Pathophysiology of Inflammatory Bowel Diseases. The New England Journal of Medicine, 383(27), 2652-2664. https://doi.org/10.1056/NEJMra2002697

Nishida, A., Inoue, R., Inatomi, O., Bamba, S., Naito, Y., & Andoh, A. (2018). Gut microbiota in the pathogenesis of inflammatory bowel disease. Clinical Journal of Gastroenterology, 11(1), 1-10. https://doi.org/10.1007/s12328-017-0813-5

Ahlawat, S., Kumar, P., Mohan, H., Goyal, S., & Sharma, K. K. (2021). Inflammatory bowel disease: tri-directional relationship between microbiota, immune system and intestinal epithelium. Critical Reviews in Microbiology, 47(2), 254-273. https://doi.org/10.1080/1040841X.2021.1876631

Geremia, A., Biancheri, P., Allan, P., Corazza, G. R., & Di Sabatino, A. (2014). Innate and adaptive immunity in inflammatory bowel disease. Autoimmunity Reviews, 13(1), 3-10. https://doi.org/10.1016/j.autrev.2013.06.004

Liu, J. Z., Jellbauer, S., Poe, A. J., Ton, V., Pesciaroli, M., Kehl-Fie, T. E., Restrepo, N. A., Hosking, M. P., Edwards, R. A., Battistoni, A., Pasquali, P., Lane, T. E., Chazin, W. J., Vogl, T., Roth, J., Skaar, E. P., & Raffatellu, M. (2012). Zinc Sequestration by the Neutrophil Protein Calprotectin Enhances Salmonella Growth in the Inflamed Gut. Cell Host & Microbe, 11(3), 227-239. https://doi.org/10.1016/j.chom.2012.01.017

Xiang, B., Dong, Z., & Dai, C. (2021). The diagnostic and predictive value of fecal calprotectin and capsule endoscopy for small-bowel Crohn's disease: a systematic review and meta-analysis. Revista Española de Enfermedades Digestivas, 113(3), 193-201. https://doi.org/10.17235/reed.2020.6996/2020

Ricciuto, A., & Griffiths, A. M. (2019). Clinical value of fecal calprotectin. Critical Reviews in Clinical Laboratory Sciences, 56(5), 307-320. https://doi.org/10.1080/10408363.2019.1619159

Lee, J. (2016). Fecal Calprotectin in Inflammatory Bowel Disease. The Korean Journal of Gastroenterology, 67(5), 233-237. https://doi.org/10.4166/kjg.2016.67.5.233

Ayling, R. M., & Kok, K. (2018). Chapter Six - Fecal Calprotectin. Advances in Clinical Chemistry, 87, 161-190. https://doi.org/10.1016/bs.acc.2018.07.005

Khaki-Khatibi, F., Qujeq, D., Kashifard, M., Moein, S., Maniati, M., & Vaghari-Tabari, M. (2020). Calprotectin in inflammatory bowel disease. Clinica Chimica Acta, 510, 556-565. https://doi.org/10.1016/j.cca.2020.08.025

Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019). The role of short-chain fatty acids in microbiota-gut-brain communication. Nature Reviews Gastroenterology & Hepatology, 16(8), 461-478. https://doi.org/10.1038/s41575-019-0157-3

Zhang, Z., Zhang, H., Chen, T., Shi, L., Wang, D., & Tang, D. (2022). Regulatory role of short-chain fatty acids in inflammatory bowel disease. Cell Communication and Signaling, 20, 64. https://doi.org/10.1186/s12964-022-00869-5

Sun, M., Wu, W., Liu, Z., & Cong, Y. (2017). Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. Journal of Gastroenterology, 52(1), 1-8. https://doi.org/10.1007/s00535-016-1242-9

Parada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H., Faber, K. N., & Hermoso, M. A. (2019). Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Frontiers in Immunology, 10, 277. https://doi.org/10.3389/fimmu.2019.00277

Downloads

Published

2023-03-28

How to Cite

Stepanov, Y. M., Klenina, I. A., Tatarchuk, O. M., Stoikevych, M. V., Tarasova Т. S., Fedorova, N. S., & Petishko, O. P. (2023). Association between calprotectin and volatile fatty acids in patients with inflammatory bowel diseases. Zaporozhye Medical Journal, 25(2), 142–146. https://doi.org/10.14739/2310-1210.2023.2.263222

Issue

Vol. 25 No. 2 (2023): Zaporozhye medical journal

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)